Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 3:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2545–2568 of 33,216 matching trials from the live ClinicalTrials.gov search.
Completed Phase 1Phase 2 Interventional Results available

Dipyridamole for Immune Activation in HIV

NCT02121756
Conditions
HIV Infection
Interventions
Dipyridamole, Placebo, then Dipyridamole
Drug
Lead sponsor
Sharon Riddler
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Cystic Fibrosis
Interventions
Ataluren
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
6 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • Long Beach, California • Palo Alto, California + 12 more
Conditions
Overactive Bladder
Interventions
trospium chloride, placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
La Mesa, California
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Biomarker Assessment of Glutamatergic Target Engagement

NCT02134951
Conditions
Healthy Controls
Interventions
Ketamine, Normal saline
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Sacramento, California • New Haven, Connecticut • New York, New York
Conditions
Atrial Fibrillation
Interventions
Ranolazine, Dronedarone, Ranolazine placebo, Dronedarone placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
15
States / cities
Beverly Hills, California • Newport Beach, California • San Francisco, California + 12 more
Terminated Phase 4 Interventional Results available

Naltrexone/Bupropion Cardiovascular Outcomes Study

NCT02638129
Conditions
Obesity, Cardiovascular Diseases
Interventions
Naltrexone HCl/Bupropion HCl ER, Placebo
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
139
States / cities
Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 136 more
Conditions
Alzheimer Disease
Interventions
CT1812, Placebo
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Conditions
Social Anxiety Disorder
Interventions
PH94B Nasal Spray, Placebo Nasal Spray
Drug
Lead sponsor
VistaGen Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
21
States / cities
Los Angeles, California • Orange, California • Riverside, California + 18 more
Conditions
Schizophrenia
Interventions
SEP-363856, Placebo, SEP-363856 Open Label
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Glendale, California • Long Beach, California
Conditions
Atopic Dermatitis
Interventions
S-777469 400 mg, S-777469 800 mg, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 65 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
33
States / cities
Hot Springs, Arkansas • Los Angeles, California • Oceanside, California + 28 more
Active, not recruiting Phase 3 Interventional Results available

Myasthenia Gravis Inebilizumab Trial

NCT04524273
Conditions
Myasthenia Gravis
Interventions
inebilizumab, IV Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
16
States / cities
Orange, California • New Haven, Connecticut • Washington D.C., District of Columbia + 13 more
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
Transcranial Magnetic Stimulation (TMS) - Standard maintenance rTMS:, Transcranial Magnetic Stimulation (TMS) - Clustered maintenance rTMS:, Transcranial Magnetic Stimulation (TMS) -- Sham maintenance rTMS
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
San Diego, California • New York, New York
Conditions
Focal Epilepsy
Interventions
ENX-101
Drug
Lead sponsor
Engrail Therapeutics INC
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
38
States / cities
Phoenix, Arizona • Tucson, Arizona • Downey, California + 31 more
Conditions
Epilepsy
Interventions
Lacosamide, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
4 Years to 16 Years
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
13
States / cities
Boulder, Colorado • Orlando, Florida • Tampa, Florida + 10 more
Conditions
Atherosclerosis
Interventions
rilapladib, placebo, 18F Fluorodeoxylucose (FDG)-PET
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 80 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Boston, Massachusetts • Brockton, Massachusetts • Haverhill, Massachusetts + 4 more
Conditions
Coronary Artery Disease
Interventions
Stem Cell Therapy, Control (plasma)
Biological · Other
Lead sponsor
Texas Heart Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2023
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-935

NCT02201056
Conditions
Healthy Volunteers
Interventions
TAK-935, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
19 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lincoln, Nebraska
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Efficacy of Olibra: A 12 Week Controlled Trial

NCT01416051
Conditions
Overweight, Obesity
Interventions
Olibra, Placebo
Dietary Supplement · Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 60 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Hypercholesteremia
Interventions
Gemcabene, Placebo
Drug
Lead sponsor
NeuroBo Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
24
States / cities
Birmingham, Alabama • Beverly Hills, California • Huntington Park, California + 19 more
Conditions
Ulcerative Colitis
Interventions
Filgotinib, PTM filgotinib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
61
States / cities
Dothan, Alabama • Scottsdale, Arizona • Long Beach, California + 53 more
Conditions
Diabetes Mellitus Type 2
Interventions
DPP-IV Inhibitor, Metformin, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
20
States / cities
Concord, California • Salinas, California • San Diego, California + 17 more
Conditions
Hypercholesterolemia
Interventions
Disodium Ascorbyl Phytostanol Phosphate (FM-VP4)
Drug
Lead sponsor
Forbes Medi-Tech
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Timeline
Started 2005
U.S. locations
14
States / cities
Mobile, Alabama • San Diego, California • Daytona Beach, Florida + 10 more
Not listed Phase 1 Interventional Accepts healthy volunteers

Investigating the Effect of Obicetrapib on Lipoprotein Metabolism

NCT05972278
Conditions
Lipid Metabolism
Interventions
Obicetrapib
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Roflumilast, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
1,568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
151
States / cities
Bayou La Batre, Alabama • Birmingham, Alabama • Huntsville, Alabama + 131 more